EP 4096630 A1 20221207 - TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF-LIFE
Title (en)
TOPICAL ROFLUMILAST FORMULATION HAVING IMPROVED DELIVERY AND PLASMA HALF-LIFE
Title (de)
TOPISCHE ROFLUMILAST-FORMULIERUNG, DIE EINE VERBESSERTE ABGABE UND PLASMAHALBWERTSZEIT AUFWEIST
Title (fr)
FORMULATION DE ROFLUMILAST TOPIQUE AYANT UNE ADMINISTRATION ET UNE DEMI-VIE PLASMATIQUE AMÉLIORÉES
Publication
Application
Priority
- US 202016778845 A 20200131
- US 2021015740 W 20210129
Abstract (en)
[origin: WO2021155173A1] The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
IPC 8 full level
A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/44 (2006.01); A61K 47/10 (2017.01); A61P 17/00 (2006.01); A61P 17/04 (2006.01)
CPC (source: EP IL KR)
A61K 9/0014 (2013.01 - EP IL KR); A61K 9/06 (2013.01 - EP IL KR); A61K 9/107 (2013.01 - KR); A61K 31/44 (2013.01 - EP IL KR); A61K 47/10 (2013.01 - EP IL KR); A61K 47/24 (2013.01 - KR); A61P 17/00 (2018.01 - EP IL KR); A61P 17/04 (2018.01 - EP IL KR); A61P 29/00 (2018.01 - KR); A61K 2300/00 (2013.01 - IL KR)
C-Set (source: EP)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2021155173 A1 20210805; AU 2021214399 A1 20220825; BR 112022015104 A2 20220927; CA 3166300 A1 20210805; CN 115551478 A 20221230; EP 4096630 A1 20221207; IL 295172 A 20220901; JP 2023513092 A 20230330; KR 20220134617 A 20221005; MX 2022009399 A 20220919
DOCDB simple family (application)
US 2021015740 W 20210129; AU 2021214399 A 20210129; BR 112022015104 A 20210129; CA 3166300 A 20210129; CN 202180017566 A 20210129; EP 21708433 A 20210129; IL 29517222 A 20220728; JP 2022546613 A 20210129; KR 20227029999 A 20210129; MX 2022009399 A 20210129